Henia Dar

CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell Carcinoma

Sumanta K. Pal, Ben Tran, John B.A.G. Haanen et al. · Cancer Discovery · 2024 · 139 citations · Full text

Medicine, Immunology, Oncology +17

558 CTX130 allogeneic CRISPR-Cas9–engineered chimeric antigen receptor (CAR) T cells in patients with advanced clear cell renal cell carcinoma: Results from the phase 1 COBALT-RCC study

Sumanta Pal, Ben Tran, John Haanen et al. · Regular and Young Investigator Award Abstracts · 2022 · 30 citations · Full text

Medicine, Immunology, Oncology +17

Preclinical Development of CTX120, an Allogeneic CAR-T Cell Targeting Bcma

Henia Dar, Daniel B. Henderson, Zinkal Padalia et al. · Blood · 2018 · 23 citations

Life Sciences, Immunology, Oncology +14

Abstract ND02: CTX112 and CTX131: Next-generation CRISPR/Cas9-engineered allogeneic (allo) CAR T cells incorporating novel edits that increase potency and efficacy in the treatment of lymphoid and solid tumors

Jonathan Terrett, Demetrios Kalaitzidis, Mary‐Lee Dequéant et al. · Cancer Research · 2023 · 17 citations

Life Sciences, Immunology, Oncology +17

A phase 1/2, open-label, multicenter, dose escalation and cohort expansion study of the safety and efficacy of anti-CD70 allogeneic CRISPR-Cas9–engineered T cells (CTX131) in adult patients with relapsed or refractory solid tumors.

Sumanta K. Pal, Melissa A. Reimers, Benjamin Garmezy et al. · Journal of Clinical Oncology · 2024 · 10 citations

Life Sciences, Immunology, Oncology +17